Physician testing for HIV in patients treated with tenofovir disoproxil fumarate and lamivudine monotherapy for hepatitis B virus
Jillian S. Y. Lau A , Dilip Ratnam B C and Ian Woolley A C DA Monash Infectious Diseases, Monash Health, Clayton, Vic. 3168, Australia.
B Department of Gastroenterology and Hepatology, Monash Health, Clayton, Vic. 3168, Australia.
C School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic. 3168, Australia.
D Corresponding author. Email: ian.woolley@monash.edu
Sexual Health 15(1) 89-90 https://doi.org/10.1071/SH17045
Submitted: 20 February 2017 Accepted: 5 June 2017 Published: 13 July 2017
Abstract
Previously we found that local patients were often not tested for HIV prior to commencing nucleoside/nucleotide reverse transcription inhibitor (NRTI) therapy for hepatitis B virus. We performed a national cross-sectional cohort study of physician practices via an online survey. A small majority (23/44; 52%) of participants reported always testing their hepatitis B virus patients for HIV prior to NRTI therapy, and 8/44 (18%) reported testing for HIV the majority of the time. Thirteen (30%) respondents reported testing only if risk factors were present. One physician reported a patient seroconverting to HIV while on TDF monotherapy.
References
[1] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available online at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [verified 28 July 2016].[2] Davies O, Alexander H, Robinson N, Pace M, Brady M, Frater J, Fox J. Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy. J Int AIDS Soc 2014; 17 19731
| Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar |
[3] Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent pre-exposure prophylaxis. J Infect Dis 2015; 211 1211–8.
| Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent pre-exposure prophylaxis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC28XitFCjsb7N&md5=c94ea8e38fcbc274f9cc383fca561e99CAS |
[4] Deshpande S, Ko T, Roberts E, Lau JSY, Horne K, Williams J, Kiss C, Ratnam D, Woolley I. Tenofovir therapy for hepatitis B may be commonly prescribed without HIV testing. J Acquir Immune Defic Syndr 2016; 71 e53–4.
| Tenofovir therapy for hepatitis B may be commonly prescribed without HIV testing.Crossref | GoogleScholarGoogle Scholar |
[5] McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir — effects on HIV-1 replication and resistance. N Engl J Med 2007; 356 2614–21.
| 1:CAS:528:DC%2BD2sXmslKjs7o%3D&md5=2c1145dcfee1c5836db85a1652a39208CAS |
[6] Guidance: HIV in indicator conditions. HIV in Europe – working together for optimal testing and earlier care. Available online at: http://newsite.hiveurope.eu/Finalised-Projects/Guidance-HIV-Indicator-Conditions [verified 30 July 2016].
[7] European Association for the Study of the Liver. Chronic hepatitis B infection clinical practice guidelines. Available online at: http://www.easl.eu/research/ our-contributions/clinical-practice-guidelines/ detail/management-of-chronic-hepatitis-b-virus- infection/report/4 [verified 31 August 2015].
[8] GILEAD. Tenofovir disoproxil fumarate product information. Available online at: http://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/viread/viread_pi.pdf?la=en [verified 30 July 2016].
[9] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available online at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [verified 28 July 2016].
[10] World Health Organization. First-line ART for adults. Available online at: http://www.who.int/hiv/pub/guidelines/arv2013/art/artadults/en/ [verified 1 October 2016].
[11] Woolley I. Isn’t it time to talk about antiretroviral stewardship? J Chemother 2016; 28 352–4.
| Isn’t it time to talk about antiretroviral stewardship?Crossref | GoogleScholarGoogle Scholar |
